O besity is major health problem in the United States-on this, there is little debate. While improved management of cardiovascular risks has decreased the impact of obesity on mortality over time, its effect on other health problems, such as cancer risk, has not changed [3] . Obesity increases overall cancer risk and has been shown to increase risks of many carcinomas and hematopoietic cancers [2, 4, 5] . However, there are few data on the effect of obesity in sarcoma.
Obesity also increases wound complications in orthopaedic procedures and overall perioperative complications. Although one would assume that obesity would have a negative influence on healing after sarcoma surgery because of larger incisions sometimes used in these procedures, frequent use of adjuvant radiation, and medical comorbidities carried by some of these patients, this association has not been demonstrated in the literature.
Where Do We Need To Go?
The authors investigated the influence of obesity on oncologic outcomes and wound healing in a cohort of 397 patients at a single institution. In short, there was no difference between the obese and nonobese groups in local recurrence, distant metastasis, sarcoma-specific death, or wound complications. However, the literature demonstrating obesity increasing cancer risks in other cancer types are population-based studies of tens of thousands of patients. There are no complete population-based databases in the United States for sarcoma, and sarcoma is so uncommon it would be unlikely to surface in studies like the one by Alamanda et al. We need sarcomaspecific evaluations performed by multiinstitutional collaborative efforts.
How Do We Get There?
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